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Despite distinct epidemiology and outcomes, pediatric acute respiratory distress syn-
drome (PARDS) is often managed based on evidence extrapolated from treatment of 
adults. The impact of non-pulmonary processes on mortality as well as the lower mor-
tality rate compared to adults with acute respiratory distress syndrome (ARDS) renders 
the utilization of short-term mortality as a primary outcome measure for interventional 
studies problematic. However, data regarding alternatives to mortality are profoundly 
understudied, and proposed alternatives, such as ventilator-free days, may be them-
selves subject to hidden biases. Given the neuropsychiatric and functional impairment 
in adult survivors of ARDS, characterization of these morbidities in children with PARDS 
is of paramount importance. The purpose of this review is to frame these challenges in 
the context of the existing pediatric literature, and using adult ARDS as a guide, suggest 
potential clinically relevant outcomes that deserve further investigation. The goal is to 
identify important areas of study in order to better define clinical practice and facilitate 
future interventional trials in PARDS.
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iNTRODUCTiON
Pediatric intensivists were not present for either the 1994 American-European Consensus Conference 
(AECC) (1) or the 2012 Berlin re-definition (2) of acute respiratory distress syndrome (ARDS), and 
so pediatric considerations were not addressed. Despite this limitation, AECC and Berlin definitions 
were historically applied to children without modification, despite the different epidemiology and 
outcomes of pediatric ARDS. To address this deficiency, the Pediatric Acute Lung Injury Consensus 
Conference (PALICC) was convened to propose specific definitions for pediatric acute respiratory 
distress syndrome (PARDS) (3). Notable differences in the PALICC definition are use of oxygenation 
index (OI) instead of PaO2/FiO2, the ability to diagnose PARDS in the absence of arterial blood gas 
analysis by using non-invasive measures of hypoxemia based on SpO2 [oxygen saturation index 
(OSI)], and less restrictive radiographic criteria.
Irrespective of definitions utilized, cohort studies and clinical trials have generally demonstrated 
lower mortality for PARDS (relative to adult ARDS), as well as an appreciable decrease in mortality 
over time (4, 5). Adult studies have demonstrated decreased pulmonary capacity, decreased quality 
of life, and worsened neurocognition among survivors of ARDS (6–8); however, comparable studies 
are lacking in PARDS. An appreciation of long-term sequelae is important for characterizing the 
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epidemiology of this syndrome. Additionally, the already low and 
further decreasing mortality rate makes short-term survival an 
impractical endpoint for most clinical trials in PARDS, neces-
sitating the identification of clinically relevant patient-centered 
outcomes to test future interventions. The purpose of this review 
is to identify the challenges in identifying appropriate outcomes 
for current and future studies in PARDS, framed in the context 
of the existing literature. Additionally, using adult ARDS studies 
as a guide, potential alternative outcomes that deserve further 
investigation in PARDS are suggested.
MORTALiTY
Pediatric acute respiratory distress syndrome has lower mortality 
than adult ARDS (4, 5), with mortality decreasing over time. 
Unfortunately, short-term mortality  –  such as 28- to 60-day 
mortality, pediatric intensive care unit (PICU) mortality, and 
hospital mortality – remains an objective, easily obtained, clini-
cally relevant, and patient-centered outcome. As such, it is the 
most consistently reported endpoint in cohort studies (Table 1) 
(5, 9–23) and in clinical trials (Table 2) (24–32). However, predic-
tors of mortality in PARDS are often not specific to PARDS but 
are characteristic of risk factors in several conditions that result in 
critical illness. Notably, immunocompromised status (5, 21, 26) 
and multisystem organ failure (MSOF) (5, 12, 17) are associated 
with increased mortality risk in several PARDS studies, includ-
ing clinical trials (26). However, immunocompromised status 
and MSOF have little pulmonary specificity, are associated with 
mortality in sepsis, and are component variables of severity of 
illness scoring systems. Thus, a generalization of this observa-
tion states that children die with PARDS, rather than because 
of PARDS. In such cases, the associated PARDS has resolved at 
the time of death, despite the persistence of mechanical ventila-
tion. Further complicating the use of mortality as an endpoint is 
elective withdrawal of potentially futile care, either for persistent 
MSOF, underlying refractory malignancy, or for presumed poor 
neurologic prognosis, none of which are specific for PARDS.
One example is worth examining in further detail. A 
multicenter randomized controlled trial (RCT) of exogenous 
surfactant (calfactant) in moderate and severe PARDS (OI > 7) 
demonstrated improved mortality associated with calfactant 
treatment (26). However, imbalance in the proportion of 
immunocompromised patients, with over-representation in the 
placebo arm, likely contributed to this effect, and after adjust-
ment for immunocompromised status, the association between 
calfactant treatment and improved mortality was no longer 
evident (p  =  0.07). Furthermore, patients received treatment 
within 48 h of intubation, but the proportion of patients success-
fully extubated did not differ between the groups and curves for 
cumulative successful extubation did not begin to diverge until 
12 days after intubation, suggesting that factors unrelated to the 
initial PARDS insult, such as immunocompromised status, may 
have been responsible for mortality and prolonged ventilation. A 
follow-up trial of calfactant was restricted to immunocompro-
mised children [Calfactant for Acute Lung Injury in Pediatric 
Stem Cell Transplant and Oncology Patients (CALIPSO)] using 
mortality as the primary outcome.
While mortality may be problematic as a primary endpoint for 
a general PARDS population, there remain subgroups of children 
with PARDS who still have a substantial mortality risk, yet with a 
reasonable chance of survival. CALIPSO is an example of limiting 
an intervention to a subgroup of PARDS with substantial mortal-
ity (>50%), albeit at the risk of difficult recruitment and reduced 
generalizability. Indeed, recently, successful trials in adult ARDS 
of neuromuscular blockade (33) and prone positioning (34) 
employed this strategy, as ARDS et Curarisation Systematique 
(ACURASYS) limited enrollment to patients with PaO2/FiO2 
≤150, rather than the typical ≤300. Prone position in severe 
ARDS (PROSEVA) required even more stringent enrollment 
criteria, as it requires PaO2/FiO2 ≤150 after 12–24  h of initial 
stabilization, thereby excluding patients who rapidly improved 
with standard ventilator management. In both cases, the goal 
was enrichment of a higher risk population in which the tested 
intervention could plausibly impact mortality with a reasonable 
sample size. This, simultaneously, avoids unnecessarily exposing 
patients to treatment when they have low risk of mortality and 
high probability of survival irrespective of randomization arm, 
thereby diluting any potential treatment effect. For PARDS to 
reproduce this, predictors of mortality risk need to be identified 
and validated. These predictors need to be available early in the 
PARDS course to allow enrollment within a timeframe amenable 
for interventions to work, ideally within 48 h of PARDS onset. 
This strategy has particular appeal for testing interventions for 
“refractory” PARDS, such as high-frequency oscillatory ventila-
tion (HFOV), prone positioning, methylprednisolone, inhaled 
nitric oxide (iNO), and extracorporeal membrane oxygenation 
(ECMO).
DURATiON OF MeCHANiCAL 
veNTiLATiON
Duration of ventilation is a common outcome described in PARDS 
studies, especially when this outcome is limited to survivors. This 
outcome has face validity, as more severe PARDS can reasonably 
be expected to require a longer duration of mechanical ventila-
tion. The 2012 Berlin definition (2) demonstrated an increase in 
duration of mechanical ventilation in survivors across increasing 
severity classes of ARDS, which was confirmed in LUNG SAFE 
(Large Observational Study to Understand the Global Impact of 
Severe Acute Respiratory Failure) (35). This observation has been 
corroborated in PARDS when using oxygenation at 24 h, rather 
than at PARDS onset (5).
To be used as a valid endpoint, the definition of “duration of 
mechanical ventilation” needs to be limited to survivors, given 
the risk of contamination of this endpoint with non-survivors 
with a short-duration of ventilation. Alternatively, liberation 
from ventilation can be analyzed as the primary outcome of 
interest, with death treated as a competing outcome. Appropriate 
statistical techniques must be employed for quantifying the effect 
of an intervention while accounting for competing events (36). 
Furthermore, given the increased utilization of non-invasive 
ventilation both prior to (37–39) and after endotracheal intuba-
tion, duration of mechanical ventilation requires clear definition 
TABLe 1 | Reported outcomes in cohorts using PARDS-type inclusion criteria and ≥100 patients.
Years Centers Countries Cases Outcomes Comments Reference
1986–1990 1 USA 100 Mortality (72%) PaO2 ≤75 with FiO2 ≥0.5; bilateral infiltrates; 74% 
immunocompromised
(9)
1990–1991 14 France 123 Mortality (60%) Intubated; FiO2 ≥0.5 on PEEP; bilateral infiltrates (10)
1993–1995 1 Canada 131 Mortality (27%) Intubated; PEEP ≥6 and FiO2 ≥0.5 for 12 h (11)
Ventilator days survivors (8, 
range 1–27)
1997–1998 10 USA, Canada 232 Mortality (40%) Intubated; HFOV (22)
1996–2000 2 USA 328 Mortality (22%) Non-invasive and intubated; AECC ALI with PF ≤300 (12)
VFD (15 ± 11)
2004–2005 12 Australia, New Zealand 117 Mortality (35%) Non-invasive and intubated; AECC ALI with PF ≤300 (13)
2005–2006 26 China 358 Mortality (44%) Any respiratory support; AECC ALI with PF ≤300 (14)
2000–2007 1 USA 398 Mortality (20%) Intubated; PF ≤300; 192 with bilateral infiltrates (15)
VFD (17, IQR 0–24)
2007–2010 5 USA 168 Mortality (11%) Intubated; AECC ALI with PF ≤300; excluded SCT (16)
VFD (20, IQR 10–23)
2009–2010 7 USA, Canada, Belgium, 
Switzerland, Netherlands
328 Mortality (38%) Intubated; HFOV (23)
2010–2011 21 Spain 146 Mortality (26%) Intubated; AECC ARDS with PF ≤200 (17)
2009–2011 7 Italy, Spain, France, 
Austria, Netherlands
221 Mortality (17%) Intubated; Berlin ARDS with PF ≤300; age 1–18 months (18)
ECMO/death (19%)
2009–2013 1 USA 312 Mortality (22%) Intubated; Berlin ARDS with SpO2 cutoffs (19)
2008–2014 5 USA 299 Mortality (13%) Non-invasive and intubated; AECC ARDS with PF ≤200 (20)
2009–2014 12 USA 222 Mortality (60%) Intubated; SCT (21)
Ventilator days survivors (9, IQR 
4–16)
2011–2014 1 USA 283 Mortality (13%) Intubated; AECC ALI and Berlin ARDS with PF ≤300 (5)
VFD (17, IQR 3–21)
Ventilator days survivors (10, 
IQR 7–17)
AECC, American-European Consensus Conference; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; HFOV, high-frequency oscillatory ventilation; PEEP, positive 
end-expiratory pressure; PF, PaO2/FiO2; SCT, stem cell transplant; VFD, ventilator-free days.
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regarding whether non-invasive support is included. Both Berlin 
(mild) ARDS (2) and PALICC PARDS (3) definitions make 
allowances for non-invasive support, suggesting that screening 
for studies based on these criteria would allow for inclusion of 
a substantial number of non-intubated patients. This potential 
for increased enrollment needs consistent and well-delineated 
reporting of what is meant by “duration of mechanical ventilation.”
Therefore, while the endpoint “duration of ventilation in 
survivors” retains face validity and likely reflects the severity of 
PARDS, it is unclear exactly how “patient-centric” this outcome 
is. Specifically, it is unclear whether a given child would be bet-
ter served with 10  days of invasive mechanical ventilation and 
extubated to high-flow cannula or whether 8  days of invasive 
ventilation followed by 4  days of non-invasive bi-level positive 
airway pressure (BiPAP) with full-facemask interface. Indeed, the 
answer likely varies between patients for a multitude of variables, 
including sedation requirements, strength, airway status, and 
indication for intubation.
Finally, duration of ventilation in survivors is complicated by 
the prevalence of subglottic stenosis, poor secretion tolerance, 
or severe upper airway obstruction from poor airway tone as 
an indication for prolonged intubation. Such patients may wean 
appropriately to minimal invasive support given their underlying 
PARDS severity, but the actual act of removing the endotracheal 
tube may be delayed, or ultimately attempted and unsuccessful, 
for reasons related primarily to their airway. Given the substantial 
number of comorbidities described in PARDS, reasons for pro-
longed intubation unrelated to the actual PARDS risk factor have 
the potential to confound the utility of duration of ventilation 
as an endpoint. An alternative has been proposed to only count 
the duration of time until successful completion of an extuba-
tion readiness test, irrespective of whether or not the patient is 
actually extubated (40). However, this has not been validated nor 
described in an actual practice or trial and does not address the 
prior criticism of not being patient-centered, as the child remains 
intubated.
veNTiLATOR-FRee DAYS
Perhaps, the most commonly adopted surrogate endpoint in 
PARDS trials, recently (Table  2), is ventilator-free days (VFD) 
at some arbitrary endpoint (e.g., at 28 days). VFD at 28 days are 
typically derived by subtracting duration of ventilation in sur-
vivors from 28 and scoring non-survivors and those requiring 
TABLe 2 | Reported outcomes in select placebo-controlled randomized clinical trials in acute respiratory failure and PARDS.
Trial Years intervention Total 
subjects
Primary outcome Other reported outcomes Reference
HFOV 1990–1994 HFOV versus 
conventional
58 Mortality (34% HFOV; 41% 
conventional)
Ventilator days in survivors; supplemental O2 
requirement; chronic lung disease
(24)
Weaning 
protocol
1999–2001 Protocolized PSV or VSV 
versus no protocol
179 Days to extubation (median 2 for no 
protocol; 1.6 PSV; 1.8 VSV)
Successful extubation (25)
Calfactant 2000–2003 Intratracheal calfactant 
versus air placebo
152 VFD (13 ± 8 for calfactant; 12 ± 11 
for air)
Mortality; failure of conventional ventilation; 
oxygenation; supplemental O2 requirement; 
PICU and hospital LOS
(26)
Prone 
position
2001–2004 Prone versus supine 
position
101 VFD (16 ± 8 for supine; 16 ± 8 for 
prone)
Mortality; organ failure-free days; supplemental 
O2 requirement; PCPC; POPC
(27)
Inhaled 
nitric oxide
2003–2005 iNO versus nitrogen 
placebo
53 VFD (15 ± 8 for iNO; 9 ± 9 for 
placebo)
Mortality; ECMO/death (28)
Lucinactant 2007–2010 Intratracheal lucinactant 
versus air placebo
165 Adjusted LSM of ventilator days (4 
for lucinactant; 4.5 for air)
Mortality; VFD; PICU and hospital LOS (29)
PED-
CARDS
2008–2010 Intratracheal calfactant 
versus air placebo
109 Mortality (12% for calfactant; 9% 
for air)
VFD; oxygenation; PICU and hospital LOS (30)
RESTORE 2009–2013 Protocolized sedation 
versus usual care
2449 Ventilator days (median 6.5 for 
protocol; 6.5 for usual care)
Mortality; duration of weaning; duration of  
non-invasive ventilation; PICU and hospital LOS
(31)
Steroids 2010–2014 Methylprednisolone 
versus placebo
35 Ventilator days (10 ± 7 for steroids; 
10 ± 5 for placebo)
Mortality; VFD; oxygenation; PICU and hospital 
LOS
(32)
ECMO, extracorporeal membrane oxygenation; HFOV, high-frequency oscillatory ventilation; LSM, least squares means; LOS, length of stay; PCPC, pediatric cerebral performance 
category; PED-CARDS, pediatric calfactant in acute respiratory distress syndrome; POPC, pediatric overall performance category; PICU, pediatric intensive care unit; PSV, pressure-
support ventilation; RESTORE, randomized evaluation of sedation titration for respiratory failure; VFD, ventilator-free days; VSV, volume support ventilation.
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≥28 ventilator days as 0 (41). It has also been defined as “days 
alive and free of mechanical ventilation” (42), which creates 
confusion for cases where the patient is extubated on day 10, but 
dies on day 20 (10 days alive and free of mechanical ventilation 
is VFD =  10; non-survival at day 28 suggests VFD =  0). This 
composite endpoint combines mortality and duration of ventila-
tion by penalizing non-survivors, unlike duration of ventilation. 
Similar to duration of ventilation in survivors, VFD at 28 days 
has demonstrated correlation across severity of Berlin ARDS 
(2) and PALICC PARDS (3) categories, with worse oxygenation 
categories associated with fewer VFD. This composite endpoint 
potentially represents efficiency, as an outcome of an interven-
tion, which both reduces mortality and duration of ventilation, 
can be detected with a smaller sample size (42).
The same caveats regarding clarity of non-invasive support are 
required for VFD as mentioned for duration of ventilation (41). 
However, VFD has a major limitation as a composite endpoint, 
as the merged individual endpoints (mortality and ventilator 
duration) are not equivalent and interchangeable. A child requir-
ing 30 days of mechanical ventilation, but surviving, cannot be 
considered identical to a child who dies after 7 days of ventila-
tion, although both would be recorded as VFD = 0. Composite 
endpoints are best utilized when the separate endpoints are of 
equivalent importance for the patient, such as stroke or myocar-
dial infarction in hypertensive adults. When initially described 
for adult ARDS, VFD was demonstrated to be useful only when 
the more pejorative outcome of mortality was improved along-
side duration of ventilation (42). Given the >30% mortality in 
adult ARDS (35), this is a reasonable expectation: interventions 
which shorten ventilation should improve mortality, assuming 
mechanical ventilation and ARDS are in the causal pathway for 
non-survival. However, even in adults, this assumption can be 
problematic. The ARDSNet corticosteroid trial (43) failed to 
demonstrate superiority of methylprednisolone for persistent 
ARDS for the primary outcome of mortality at 60 days (29.2% 
mortality in methylprednisolone, 28.6% in placebo, p  =  1). 
However, methylprednisolone treatment was associated with 
4.4 additional VFD and 2.7 additional ICU-free days at 28 days. 
Significantly, more patients in the methylprednisolone arm 
required re-initiation of ventilation (28 versus 9%, p =  0.006). 
These discrepant results make interpretation of the trial difficult: 
mortality is reported at 60 days, but VFD at 28 days. Mortality is 
nominally higher in the methylprednisolone group, but VFD are 
also more favorable for methylprednisolone. Thus, in this case, 
the reporting of VFD offers no advantages or power relative to 
reporting on mortality alone: when an intervention has opposite 
effects on duration of ventilation and mortality, VFD merely 
confuses the interpretation.
In pediatrics, the utilization of VFD at 28 days is potential sus-
pect for these same reasons, as PARDS mortality is much lower, 
and persistent hypoxemia is unlikely to be the cause of mortality. 
Thus, the effect on mortality is less certain to be in the same direc-
tion as duration of ventilation. For instance, a trial of ECMO for 
severe refractory PARDS may result in improved nominal mor-
tality rates but would likely result in prolonged duration of venti-
lation, thereby complicating the interpretation and utility of VFD. 
Finally, several interventions sorely in need of testing in PARDS, 
including fluid management, sedation protocols, weaning, and 
extubation readiness all clearly impact length of ventilation much 
more so than they will impact mortality, hampering the utility of 
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VFD as an outcome unless these parameters are protocolized in 
the context of the trial.
NeeD FOR eXTRACORPOReAL SUPPORT 
AS AN OUTCOMe
A more recently reported composite outcome for PARDS inves-
tigations has been the composite of need for ECMO or death 
(18, 28). This attempts to address the limitations of VFD and the 
low mortality (and thus difficult to adequately power) of PARDS. 
The underlying assumption is that lung injury severe enough to 
require ECMO is essentially refractory to conventional mechani-
cal ventilation, and thus need for ECMO would be a death in 
any center unable to provide ECMO. Therefore, “ECMO” is 
close enough to “death” to justify combination as a composite 
endpoint.
The European Society for Pediatric and Neonatal Intensive 
Care (ESPNIC) used this definition to test the utility of the Berlin 
criteria in children (18) and demonstrated that the inclusion of a 
“severe” ARDS category improved validity with an increased risk 
of ECMO/death in children with Berlin-defined severe ARDS, 
whereas risks were similar when defined using AECC definitions. 
It should be noted, however, that the incidence of ECMO/death 
(18.6%) was only marginally increased over the incidence of 
mortality (17.2%), and that comparable analyses for the outcome 
mortality yielded identical conclusions.
A recently published RCT (28) for iNO (total n = 53) reported 
both mortality (28% placebo, 8% iNO, χ2 p = 0.07) and ECMO/
death (48% placebo, 8% iNO, p < 0.01). The trial was powered 
for a difference in VFD at 28 days, for which it required a sample 
size of 169 children, and was stopped early for slow enrollment. 
Of note, the difference in the reported VFD in this trial was 
also significant. While the primary outcome of more VFD was 
achieved despite the small sample size, the reporting of ECMO/
death in this study points to a potential mechanism, whereby 
iNO improved VFD. Specifically, exposure to iNO appeared to 
decrease the rate of ECMO utilization, suggesting an improve-
ment in hypoxemia, thereby reducing total ventilator days and 
potentially impacting mortality. This is significant, as it implies 
a connection between improvement in hypoxemia and better 
outcomes in PARDS, a connection which is not consistently cor-
roborated in adult ARDS trials (44). For certain trials of salvage 
therapy, such as methylprednisolone, iNO, prone positioning, 
and HFOV, the use of ECMO/death as a primary outcome may 
be rational. However, as in the example above, there is little 
information added by this specific reporting that was not also 
captured by the more conventional short-term outcome of VFD 
at 28 days. Additionally, as ECMO is not an outcome per se but 
simply an additional mode of supportive care, with subjective 
thresholds for its utilization among different centers and prac-
titioners, the composite outcome of ECMO/death is difficult to 
standardize. Finally, the component variables of ECMO/death 
are not of equal importance to the patient, thus calling into 
question its validity as a patient-centered, clinically meaningful 
composite outcome.
POST-DiSCHARGe OUTCOMeS
There have been no studies examining long-term mortality in 
PARDS, but outcomes, such as 90-day, 6-month, or 12-month 
mortality, are unlikely to represent significant differences com-
pared to short-term mortality. Additionally, long-term mortality 
is more likely to result from either the underlying condition or 
an unrelated cause and is unlikely to be a sequelae of PARDS. 
Therefore, alternative post-discharge outcomes are needed 
(Table 3). Recent attention has focused on the development of 
new morbidities in the PICU as a relevant outcome (45, 46), with 
up to twice the prevalence of mortality.
Few studies have investigated the physical or neurocogni-
tive quality of life in survivors of PARDS (47–51). The existing 
studies are of extremely limited sample size (all n ≤  11) and 
outdated, with ventilator management not reflective of current 
PICU practices (52, 53). In 1985, Fanconi et al. (47) published on 
pulmonary function testing (PFT) of nine survivors of PARDS 
ventilated between 1978 and 1982 (five of whom experienced 
peak pressures >40 cmH2O) at a mean 2.3-year follow-up. Seven 
of the nine were considered “hypoxemic,” with PaO2 <80 mmHg 
on room air, and eight of nine had ventilation inequalities on 
multibreath nitrogen washout. Increased peak pressures and 
increased exposure to FiO2 >0.5 during PARDS correlated 
with increased ventilation inequalities, suggesting a potential 
association between ventilator management and long-term 
pulmonary outcome. In a separate study published in 1996, 
11 PARDS survivors ventilated between 1986 and 1993 (mean 
PaO2/FiO2 160; 9 of 11 with peak pressures >40 cmH2O) with 
PFT performed at a mean 23-month follow-up demonstrated 
obstructive physiology in three children and mixed obstruction 
and restrictive physiology in an additional four children (49). 
The most recent investigation of PARDS survivors (51) occurred 
in children ventilated between 1986 and 1998 (all experienced 
pressure-controlled ventilation, with all peak pressures 
<35  cmH2O). These investigators were able to assess PFT in 
seven patients, finding one with an abnormal diffusion capacity, 
and a second with exercise-induced hypoxemia.
Based on these small case series, the PALICC group recom-
mended that survivors of PARDS undergo screening for PFT 
abnormalities within 1 year of discharge (54). The small sample 
size of these existing studies, antiquated ventilator management, 
and variable follow-up time precludes any real assessment of the 
prevalence of pulmonary dysfunction in PARDS survivors. Larger 
scale, multicenter follow-up is sorely needed, potentially exploit-
ing the infrastructure of existing pediatric critical care research 
networks and in collaboration with pediatric pulmonologists and 
rehabilitation providers.
Studies within this framework are becoming more common 
in pediatric critical care. The out-of-hospital arm of Therapeutic 
Hypothermia after Pediatric Cardia Arrest (THAPCA) trial (55) 
was powered for a primary outcome of a dichotomized (good 
versus bad) version of the Vineland Adaptive Behavior Scale, 
second edition (VABS-II). Ebrahim et  al. (56) reported on the 
1-month post-PICU admission outcome of 65 urgently admitted 
survivors using VABS-II, pediatric cerebral performance category 
TABLe 3 | Potential outcomes for PARDS studies.
Outcome Timeframe Advantages Disadvantages
Mortality Short term Easy to obtain Impractical given low baseline mortality
28 or 60 days Fixed time-point
PICU Related to acute process
Hospital Patient-centered
Medium and long term Potentially captures longer period of risk for unfavorable 
outcomes
Similarly low rate
90 days Harder to obtain follow-up
1 year More related to underlying comorbidities
VFD 28 days Easy to obtain Imbalance in components of the composite outcome
Increases power to detect clinically meaningful 
improvements related to shortened ventilation
Only increases power if intervention benefits both 
mortality and ventilator days
Ventilator days 28 days Easy to obtain Needs non-invasive support explicitly defined
PICU LOS Related to pulmonary nature of PARDS Unclear if patient-centered
ECMO/death Short term Increases power to detect efficacy of pre-ECMO  
“salvage therapies”
Subjective use of ECMO
Imbalance in components of the composite outcome
Unclear if patient-centered
Neurocognitive 
and functional 
(POPC/PCPC)
Medium and long term Rapid (POCP/PCPC) More thorough cognitive function requires longer testing
90 days Patient-centered
1 year Potentially completed over telephone Changes with developmental age and with comorbidities
Pre-return to school Potentially more practical, as it is a prevalent outcome
Pulmonary 
outcomes
Medium and long term Patient-centered
Related to pulmonary nature of PARDS
Requires infrastructure (expertise and equipment) for 
in-person follow-up90 days
1 year
Pre-return to school
Biometric 
outcomes
Medium and long term Patient-centered
Does not require return to clinic
Potentially improved response rate
Requires development, testing and validation
Requires expertise
HIPAA concerns
Ownership concerns (who owns the data and how will it 
be used?)
90 days
1 year
Pre-return to school
Psychiatric Long term Patient-centered Requires infrastructure (expertise) for in-person follow-up
Potentially completed over telephone
Health care 
utilization
Medium and long term
90 days and 1 year
re-hospitalization
Patient-centered
Does not require inpatient follow-up
Related to pulmonary nature of PARDS
Addresses cost to patient/family
Difficult to obtain
Sensitive to local practices
Potentially more related to underlying comorbidities than 
to PARDS
ECMO, extracorporeal membrane oxygenation; LOS, length of stay; PARDS, pediatric acute respiratory distress syndrome; PCPC, pediatric cerebral performance category; POPC, 
pediatric overall performance category; PICU, pediatric intensive care unit; VFD, ventilator-free days.
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(PCPC), pediatric overall performance category (POPC), and 
overall pediatric quality of life inventory, fourth edition. They 
demonstrated an overall poor quality of life for these patients at 
1-month post-PICU admission. A recent review article identified 
potentially useful health-related quality of life (HRQL) metrics 
for pediatric critical care (57). This review identified substantial 
morbidity for PICU survivors, some of which were associated with 
treatments received during their PICU stay, suggesting possible 
modifiable risk factors. Additionally, a recent review has also sug-
gested significant psychiatric morbidity in PICU survivors (58), 
including post-traumatic stress disorder (PTSD), depression, and 
behavioral disorders, with prevalence of post-traumatic stress 
symptoms potentially as high as 62% (59). Finally, the ongoing 
multicenter Life after Pediatric Sepsis Evaluation (LAPSE) study 
is a prospective observational study collecting information on 
quality of life, family dynamics and stress, and health care utiliza-
tion in survivors of pediatric severe sepsis.
ADULT ARDS iNveSTiGATiONS OF 
ALTeRNATive OUTCOMeS
Seminal work in adult ARDS long-term outcome (6, 7) has paved 
the way for potentially comparable studies in PARDS. In 2002, 
adult survivors of moderate and severe ARDS were followed 
at 3, 6, and 12 months, with a primary outcome of 6-min walk 
distance (6). The authors found that survivors of ARDS (median 
age 45  years) had persistent physical limitations at all time-
points tested, primarily due to muscle wasting and weakness. 
At 12  months, only 49% of patients had returned to work. In 
multivariable regression, use of corticosteroids and duration of 
mechanical ventilation both negatively affected 6-min walk dis-
tance, suggesting a possible relationship between modifiable risk 
factors and medium-term functional outcome. In the subsequent 
5-year follow-up study, the median 6-min walk distance remained 
below predicted values (7). However, pulmonary function had 
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returned to near normal, and persistent exercise limitations 
were attributed to continuing weakness and neuropsychological 
impairments. Health-care costs continued to be substantial for 
survivors up to 5 years after discharge, especially in those with 
pre-existing comorbidities.
For PARDS investigators, this experience is instructive. The 
major strengths of these studies are the well-characterized, 
multicenter cohort, the longitudinal study design, the high rates 
of follow-up, and the in-person data collection. The granularity 
of the data allowed significant associations to be made regarding 
ICU exposures (e.g., corticosteroids) and subsequent medium- 
and long-term outcomes. While these observations remain 
hypothesis-generating, these are still essential initial steps toward 
determining how to design future prospective trials with clini-
cally meaningful, patient-centered outcomes.
An earlier study employing an alternative design is also 
worth considering (60). A prospective case control interview/
questionnaire study was performed of adult ARDS survivors 
matched with non-ARDS survivors with similar severity of ill-
ness at a median of 23 months after discharge. ARDS survivors 
demonstrated worse HRQL in nearly all domains tested, includ-
ing respiratory-specific domains. The most profound reduc-
tions in ARDS survivors were in the domains assessing either 
physical limitations or on the impact of pulmonary symptoms 
on activities of daily living. This was the first study to assess the 
HRQL in ARDS survivors matched to similarly ill non-ARDS 
patients, thus minimizing the possibility that observations were 
simply reflections of severity of illness; rather, this study design 
increased the plausibly that these associations were either actu-
ally caused by having ARDS specifically, or conversely, by the 
treatments used for it.
The significance of long-term, patient-centered outcomes is 
elegantly made when considering the neuropsychological func-
tion in adult ARDS survivors of the fluid and catheter treatment 
trial (FACTT). The initial trial used a 2 × 2 factorial design to 
test (separately) the utility of pulmonary-artery catheters versus 
central-venous catheters, and the effects of a conservative ver-
sus a liberal fluid management strategy on hemodynamically 
stable ARDS patients (61, 62). The trial failed to demonstrate 
superiority of either fluid strategy in its primary outcome of 
60-day mortality (25.5% mortality in fluid conservative, 28.4% 
in fluid liberal, p = 0.30). However, the conservative arm resulted 
in 2.5 more VFD (p < 0.001) and 2.2 additional ICU-free days 
(p < 0.001) (61) without additional increase in non-pulmonary 
organ failures. Based on these findings, the FACTT investigators 
recommended a conservative fluid strategy in hemodynamically 
stable ARDS patients.
The follow-up ARDS cognitive outcome study (ACOS) 
conducted telephone interviews of FACTT survivors at 2 and 
12  months post-discharge (8). Similar to prior investigations 
(6, 60), the investigators found that most survivors (55–60%, 
depending on metric used) experienced long-term cognitive 
impairment. Interestingly, lower PaO2 (p = 0.015) and allocation 
to the conservative fluid arm (p =  0.005) were independently 
associated with long-term cognitive impairment. The PaO2 dur-
ing ARDS reported in ACOS survivors with cognitive impair-
ment was median 71 (interquartile range 67–80), well within 
the ARDSNet recommended PaO2 ranges of 55–80, suggesting 
that existing, arbitrary guidelines may be too permissive, and 
that this level of mild hypoxemia may be associated with long-
term neurologic sequelae. Additionally, the conclusions of the 
FACTT trial that conservative fluid management resulted in 2.5 
additional VFD without additional organ failures are now called 
into question, as 12-month neurologic function clearly suggests 
potential sub-clinical neurologic dysfunction, leading to long-
term functional impairment. To date, no study in children with 
PARDS has investigated any sort of long-term outcome, and the 
efficacy of our interventions on long-term function in growing 
and developing children remains a mystery.
BiOMeTRiC OUTCOMeS
One of the disadvantages of the existing framework for evaluat-
ing long-term outcomes is the expense and expertise necessary 
to bring back patients to a follow-up clinic and conduct PFT 
and neuromuscular testing. An alternative strategy has been 
demonstrated by cardiologists with the embrace of remote 
telemonitoring (RTM) technology. These have taken the form 
of devices, which record heart rate, cardiac rhythm, pulse oxi-
metry, and blood pressure, with wireless transmission to a data 
collection center (63). Devices can be modified to also include 
brief questionnaires, adding additional data regarding subjective 
experiencing of symptoms by the patient. Home spirometry 
adapted with an automated modem for data transmission has 
been used in a trial for management of children with asthma 
(64). Device modifications exist, which can additionally measure 
grip strength, as well as assess flexibility and reaction time using 
game-playing scenarios (65), which may be able to address 
certain neurocognitive and neuromuscular outcomes in PARDS 
survivors. RTM devices have already been incorporated as inter-
ventions in clinical trials in adult heart failure (66, 67). The use of 
RTM for patients with pacemakers and implantable cardioverter 
defibrillators by pediatric cardiologists was associated with fewer 
clinic visits (68), providing proof of concept for RTM to allow 
follow-up for patients at lower cost.
Remote telemonitoring remains unexplored in pediatric 
critical illness research, although it possesses significant poten-
tial. Some of the limitations regarding patient loss to follow-up 
are nicely addressed by RTM. Platforms which may only require 
smartphones and appropriate adaptors, or which utilize gaming, 
are intuitively appealing to a pediatric population, and may 
improve compliance. However, expertise in development and 
interpretation are still necessary, and validation will be required 
prior to implementation.
CONCLUSiON
Mortality in PARDS is decreasing, and while it remains clinically 
relevant and patient-centered, it is impractical for most purposes, 
and its use should likely be limited to trials aimed at enrolling 
pre-determined higher risk groups. VFD is likely to remain the 
most common primary endpoint for clinical trials in the foresee-
able future, but advocates should be aware of its limitations, and 
should ensure that the power of this composite outcome rests 
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on whether the tested intervention improve both mortality and 
duration of ventilation in survivors. Finally, given the prevalence 
of long-term neuropsychiatric morbidity and functional impair-
ment in adult ARDS survivors, it is imperative that these param-
eters are defined for children. After a better understanding of the 
burden of surviving PARDS on patients and families is obtained, 
studies can be designed to demonstrate a return to pre-morbid 
functioning, which is fundamentally most important to the child 
and family.
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